Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait
-
Published:2022-08-09
Issue:2
Volume:6
Page:em0120
-
ISSN:2542-4904
-
Container-title:European Journal of Environment and Public Health
-
language:
-
Short-container-title:EUROPEAN J ENV PUBLI
Publisher
Modestum Publishing Ltd
Reference28 articles.
1. Abuhadida, S., Bastaki, L., Bash, B. and Alhindal, B. (2022). Return on investment from the prevention of orphan diseases in Kuwait. Annals of Public Health. https://doi.org/10.55085/aph.2022.637 2. Armstrong, E. P., Malone, D. C., Yeh, W. S., Dahl, G. J., Lee, R. L. and Sicignano, N. (2016). The economic burden of spinal muscular atrophy. Journal of Medical Economics, 19(8), 822-826. https://doi.org/10.1080/13696998.2016.1198355 3. Bertram, M. Y., Lauer, J. A., Stenberg, K. and Edejer, T. (2021). Methods for the economic evaluation of health care interventions for priority setting in the health system: An update from WHO CHOICE. International Journal of Health Policy and Management, 10(11), 673-677. https://doi.org/10.34172/ijhpm.2020.244 4. Broekhoff, T. F., Sweegers, C., Krijkamp, E. M., et al. (2021). Early cost-effectiveness of onasemnogene abeparvovec-xioi (zolgensma) and nusinersen (spinraza) treatment for spinal muscular atrophy I in The Netherlands with relapse scenarios. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(6), 759-769. https://doi.org/10.1016/j.jval.2020.09.021 5. Cantoni, E. and Ronchetti, E. (2006). A robust approach for skewed and heavy-tailed outcomes in the analysis of health care expenditures. Journal of Health Economics, 25(2), 198-213. https://doi.org/10.1016/j.jhealeco.2005.04.010
|
|